Sumatriptan
- TRADE NAMES: Alsuma (King); Imigran (GSK); Imitrex (GSK); Onzetra Xsail (Avanir); Sumavel DosePro (Endo); Zecuity (Teva)
- INDICATIONS: Migraine attacks, cluster headaches
- CLASS: 5-HT1 agonist, Serotonin receptor agonist, Triptan
- HALF-LIFE: 2.5 hours
Citalopram, Dihydroergotamine, Ergot-containing drugs, Escitalopram, Fluoxetine, Fluvoxamine, Isocarboxazid, MAO inhibitors, Methysergide, Naratriptan, Nefazodone, Paroxetine Hydrochloride, Phenelzine, Rizatriptan, Sertraline, Sibutramine, SNRIs, SSRIs, St John's Wort, Tranylcypromine, Venlafaxine, Zolmitriptan
PREGNANCY CATEGORY: C
Contra-indicated in patients with Wolff-Parkinson-White syndrome, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, severe hepatic impairment or a history of coronary artery disease, coronary vasospasm, stroke, transient ischemic attack, or hemiplegic or basilar migraine; or with recent (within 24 hours) use of another 5-HT1 agonist (e.g. another triptan) or an ergotamine-containing medication, or current or recent (past 2 weeks) use of a monoamine oxidase-A inhibitor.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sumatriptan in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
